{"favorite_id": 10054, "calc_type": "", "dosing": false, "full_title_en": "Rai Staging System for Chronic Lymphocytic Leukemia (CLL)", "short_title_en": "Rai Staging for CLL", "medium_description_en": "<span id=\"docs-internal-guid-5cc76905-8a8b-bef3-f00a-bcb7a45691ad\">Stages chronic lymphocytic leukemia, similar to <calculator id=\"10053\">Binet Staging System</calculator></span>.", "short_description_en": "CLL stage classification.", "before_use": "", "instructions_en": "<p><span id=\"docs-internal-guid-e542ee75-d76f-541d-cb2f-1985c4781009\">Use in patients with lymphocytosis (absolute lymphocytes &ge;15,000/mm<sup>3</sup> in blood and &ge;40% lymphocytes in marrow). Lymph nodes, spleen, and liver are considered enlarged if palpable on exam.</span></p>", "purpose_en": ["Diagnosis"], "disease_en": ["Hematologic Malignancy", "Cancer"], "specialty_en": ["Hematology and Oncology"], "chief_complaint_en": ["Fatigue", "Fever", "Abdominal Pain", "Weight Loss/Gain"], "system_en": ["Oncologic", "Hematologic"], "search_abbreviation_en": ["Rai staging system", "chronic lymphocytic leukemia ", "CLL"], "slug": "rai-staging-system-chronic-lymphocytic-leukemia-cll", "seo": {"meta_description_en": "The Rai Staging System for Chronic Lymphocytic Leukemia (CLL) stages chronic lymphocytic leukemia, similar to Binet Staging System.", "keywords_en": "Binet staging system, Rai staging system, CLL, chronic lymphocytic leukemia "}, "content": {"how_to_use": {"use_case_en": "<p>Do you use the&nbsp;Rai Staging System for CLL&nbsp;and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "pearls_pitfalls_en": "", "why_use_en": ""}, "next_steps": {"advice_en": "<p>Do you use the&nbsp;Rai Staging System for CLL&nbsp;and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">Selection of the appropriate features (lymphocytosis must be present for all):</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"134\" /><col width=\"134\" /><col width=\"134\" /><col width=\"47\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Lymph nodes, spleen, liver</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Hemoglobin</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Platelet count</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Rai&nbsp;Stage</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">No enlargement</p>\n</td>\n<td>\n<p dir=\"ltr\">Near normal</p>\n</td>\n<td>\n<p dir=\"ltr\">Near normal</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Enlarged lymph nodes; no spleen or liver enlargement</p>\n</td>\n<td>\n<p dir=\"ltr\">Near normal</p>\n</td>\n<td>\n<p dir=\"ltr\">Near normal</p>\n</td>\n<td>\n<p dir=\"ltr\">I</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Enlarged spleen; lymph nodes and liver may or may not be enlarged</p>\n</td>\n<td>\n<p dir=\"ltr\">Near normal</p>\n</td>\n<td>\n<p dir=\"ltr\">Near normal</p>\n</td>\n<td>\n<p dir=\"ltr\">II</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">May or may not be enlarged</p>\n</td>\n<td>\n<p dir=\"ltr\">Low</p>\n</td>\n<td>\n<p dir=\"ltr\">Near normal</p>\n</td>\n<td>\n<p dir=\"ltr\">III</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Enlarged lymph nodes, spleen, or liver</p>\n</td>\n<td>\n<p dir=\"ltr\">Low or near normal</p>\n</td>\n<td>\n<p dir=\"ltr\">Low</p>\n</td>\n<td>\n<p dir=\"ltr\">IV</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">From <a href=\"https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/detection-diagnosis-staging/staging.html\">American Cancer Society 2018</a>.</p>\n<p dir=\"ltr\">Low hemoglobin: &le;11 g/dL; low platelets: &le;100,000/mm&sup3;.</p>\n<p><span style=\"font-size: 10pt; font-family: Arial; color: #0000ff; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&nbsp;</span></p>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Rai&nbsp;Stage</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Risk group</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Overall survival</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n<td>\n<p dir=\"ltr\">Low</p>\n</td>\n<td>\n<p dir=\"ltr\">&gt;10 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">I/II</p>\n</td>\n<td>\n<p dir=\"ltr\">Intermediate</p>\n</td>\n<td>\n<p dir=\"ltr\">7 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">III/IV</p>\n</td>\n<td>\n<p dir=\"ltr\">High</p>\n</td>\n<td>\n<p dir=\"ltr\">&lt;4 years</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><span id=\"docs-internal-guid-2e156e86-8a8e-9e6c-341f-2ea7e87b2871\">From <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25461996\" target=\"_blank\">Nabhan 2014</a>.</span></p>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/1139039", "text": "Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-34."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/25461996", "text": "Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312(21):2265-76."}], "Validation": [{"href": "", "text": ""}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Kanti R. Rai", "creator_info": {"about_en": "<p>Kanti R. Rai, MD, is a principal investigator and professor at The Feinstein Institute for Medical Research in Manhasset, New York. He is also chief of the Chronic Lymphocytic Leukemia Research and Treatment Program at the North Shore-LIJ Cancer Institute. His primary research is focused on clinical leukemia and molecular therapy.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-kanti-r-rai.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Rai+KR%5Bau%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Enlarged lymph nodes", "name": "lymph", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": true}, {"type": "toggle", "label_en": "Enlarged spleen", "name": "spleen", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": true}, {"type": "toggle", "label_en": "Enlarged liver", "name": "liver", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": true}, {"type": "toggle", "label_en": "Anemia", "name": "anemia", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": "Hgb \u226411 g/dL", "optional": true}, {"type": "toggle", "label_en": "Thrombocytopenia", "name": "thrombocytopenia", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": "Platelets \u2264100,000/mm\u00b3", "optional": true}], "md5": "e99491c30fdf1e0acd0b5c28e64384c0", "related_calcs": [{"calcId": 10053, "short_title_en": "Binet Staging for CLL", "slug": "binet-staging-system-chronic-lymphocytic-leukemia-cll"}, {"calcId": 4054, "short_title_en": "CLL-IPI", "slug": "international-prognostic-index-chronic-lymphocytic-leukemia-cll-ipi"}, {"calcId": 10040, "short_title_en": "Duval/CIBMTR Score", "slug": "duval-cibmtr-score-acute-myelogenous-leukemia-aml-survival"}]}